Literature DB >> 2976080

Neuropsychological and neuroradiological correlates in Huntington's disease.

S E Starkstein1, J Brandt, S Folstein, M Strauss, M L Berthier, G D Pearlson, D Wong, A McDonnell, M Folstein.   

Abstract

Measurements of cortical and subcortical atrophy were made on CT scans of 34 patients with Huntington's disease. Significant correlations were found between the bicaudate ratio (BCR) and an eye movement scale (r = 0.44, p less than 0.01), and activities of daily living scale (r = 0.57, p less than 0.001) and the Mini-Mental State Exam (r = 0.49, p less than 0.01). No correlations were found between BCR values and severity of chorea or voluntary motor impairment. A detailed neuropsychological evaluation of 18 Huntington's disease patients showed significant correlations between the BCR and Symbol Digit Modalities test (r = 0.65, p less than 0.01), and parts A (r = 0.72, p less than 0.001) and B (r = 0.80, p less than 0.0001) of the Trail Making Test. These data support work in primates that demonstrates the role of the caudate nucleus in cognitive and oculomotor functions, but not in motor control (which is governed by putamino-subthalamic systems). The specific cognitive skills correlated with caudate atrophy in Huntington's disease are those reported in primate work to be served by the frontal-caudate loop system: eye movements, conceptual tracking, set shifting and psychomotor speed.

Entities:  

Mesh:

Year:  1988        PMID: 2976080      PMCID: PMC1032911          DOI: 10.1136/jnnp.51.10.1259

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  13 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

Review 2.  Parallel organization of functionally segregated circuits linking basal ganglia and cortex.

Authors:  G E Alexander; M R DeLong; P L Strick
Journal:  Annu Rev Neurosci       Date:  1986       Impact factor: 12.449

3.  Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey.

Authors:  L D Selemon; P S Goldman-Rakic
Journal:  J Neurosci       Date:  1985-03       Impact factor: 6.167

4.  Clinical correlates of dementia and disability in Huntington's disease.

Authors:  J Brandt; M E Strauss; J Larus; B Jensen; S E Folstein; M F Folstein
Journal:  J Clin Neuropsychol       Date:  1984-11

5.  Voluntary movement dysfunction in Huntington's disease and tardive dyskinesia.

Authors:  A S David; D V Jeste; M F Folstein; S E Folstein
Journal:  Acta Neurol Scand       Date:  1987-02       Impact factor: 3.209

6.  The assessment of changes in brain volume using combined linear measurements. A CT-scan study.

Authors:  J M Gomori; I Steiner; E Melamed; G Cooper
Journal:  Neuroradiology       Date:  1984       Impact factor: 2.804

7.  Dementia in Huntington disease: a cross-sectional analysis of intellectual decline.

Authors:  J M Fisher; J L Kennedy; E D Caine; I Shoulson
Journal:  Adv Neurol       Date:  1983

8.  Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography.

Authors:  K L Leenders; R S Frackowiak; N Quinn; C D Marsden
Journal:  Mov Disord       Date:  1986       Impact factor: 10.338

9.  The diagnosis of Huntington's disease.

Authors:  S E Folstein; R J Leigh; I M Parhad; M F Folstein
Journal:  Neurology       Date:  1986-10       Impact factor: 9.910

10.  PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.

Authors:  A B Young; J B Penney; S Starosta-Rubinstein; D S Markel; S Berent; B Giordani; R Ehrenkaufer; D Jewett; R Hichwa
Journal:  Ann Neurol       Date:  1986-09       Impact factor: 10.422

View more
  17 in total

Review 1.  Executive control functions in degenerative dementias: a comparative review.

Authors:  L M Duke; A W Kaszniak
Journal:  Neuropsychol Rev       Date:  2000-06       Impact factor: 7.444

2.  The development of a trial making test in young children: the TRAILS-P.

Authors:  Kimberly Andrews Espy; Mary F Cwik
Journal:  Clin Neuropsychol       Date:  2004-08       Impact factor: 3.535

3.  Early Detection of Huntington Disease.

Authors:  Jane S Paulsen
Journal:  Future Neurol       Date:  2010-01

4.  Cognitive and functional decline in Huntington's disease: dementia criteria revisited.

Authors:  Guerry M Peavy; Mark W Jacobson; Jody L Goldstein; Joanne M Hamilton; Amy Kane; Anthony C Gamst; Stephanie L Lessig; J C Lee; Jody Corey-Bloom
Journal:  Mov Disord       Date:  2010-07-15       Impact factor: 10.338

5.  Regional atrophy associated with cognitive and motor function in prodromal Huntington disease.

Authors:  Elizabeth H Aylward; Deborah L Harrington; James A Mills; Peggy C Nopoulos; Christopher A Ross; Jeffrey D Long; Dawei Liu; Holly K Westervelt; Jane S Paulsen
Journal:  J Huntingtons Dis       Date:  2013

6.  Behavioral Changes in Huntington Disease

Authors:  Jason Brandt
Journal:  Cogn Behav Neurol       Date:  2018-03       Impact factor: 1.600

7.  Neocortical neurotransmitter markers in Huntington's disease.

Authors:  S J Pearson; G P Reynolds
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 8.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

9.  Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study.

Authors:  Jurgen Lemiere; Marleen Decruyenaere; Gery Evers-Kiebooms; Erik Vandenbussche; Rene Dom
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

10.  Cognitive reserve and brain reserve in prodromal Huntington's disease.

Authors:  Aaron Bonner-Jackson; Jeffrey D Long; Holly Westervelt; Geoffrey Tremont; Elizabeth Aylward; Jane S Paulsen
Journal:  J Int Neuropsychol Soc       Date:  2013-05-23       Impact factor: 2.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.